



Results from samples checked by Toronto's drug checking service

July 4 – 17, 2020

[Toronto's drug checking service](#) offers people who use drugs timely and detailed information on the contents of their drugs using the most sophisticated lab-based technologies.

[Sign up](#) to receive reports, alerts, and other information on Toronto's unregulated drug supply.

Checked samples by sample type

Between July 4 – 17, 2020, 64 samples were checked: 55% (35) were substances and 45% (29) were used paraphernalia.

Checked samples by expected drug

When a sample is submitted to be checked, the drug that sample is expected to contain is recorded. Of the 64 samples checked between July 4 – 17, 2020:

- 29 were expected to be fentanyl
- 7 were expected to be cocaine
- 7 were expected to be methamphetamine
- 9 were expected to be other drugs, including: amphetamine, benzodiazepine, ketamine, lisdexamfetamine, LSD, opium, and Percocet
- 6 were expected to be a polysubstance
- 6 did not have a stated expected drug

Expected fentanyl samples

Of the 64 samples checked between July 4 – 17, 2020, 45% (29) were expected to be fentanyl (28% were substances and 72% were used paraphernalia).

Presence of fentanyl in expected fentanyl samples (29)

- 3% (1) contained no fentanyl
- 3% (1) contained only fentanyl
- 93% (27) contained fentanyl and other drugs

Expected fentanyl samples containing fentanyl and other drugs (27)

Of the 29 samples expected to be fentanyl, 93% (27) **contained fentanyl and other drugs**. Other drugs found included:

- 93% (25) contained caffeine
- 63% (17) contained despropionyl fentanyl (4-ANPP)*
- 59% (16) contained one or more benzodiazepine or benzodiazepine-related drug*:
 - 59% (16) contained etizolam*
 - 19% (5) contained flualprazolam*
 - 4% (1) contained clonazepam*
 - 4% (1) contained flubromazolam*
- 41% (11) contained heroin
- 41% (11) contained norfentanyl*
- 33% (9) contained 6-MAM (heroin-related)
- 33% (9) contained acetyl fentanyl*
- 30% (8) contained cocaine
- 30% (8) contained methamphetamine
- 19% (5) contained furanyl UF-17 (opioid-related)*
- 15% (4) contained fentanyl (hydroxy)*
- 7% (2) contained ACHMINACA (synthetic cannabinoid-related)*
- 4% (1) contained phenacetin*

Other expected drug samples containing unexpected noteworthy drugs

Of the remaining 35 samples checked between July 4 – 17, 2020, meaning samples that were not expected to be fentanyl, 20% (7) contained one or more unexpected noteworthy drug. Unexpected noteworthy drugs found included:

- 29% (2) of **expected cocaine** samples contained phenacetin*
- 14% (1) of **expected methamphetamine** samples contained levamisole*
- 33% (2) of samples that **did not have a stated expected drug** contained phenacetin*
- 17% (1) of samples that **did not have a stated expected drug** contained one or more benzodiazepine or benzodiazepine-related drug*
- 17% (1) of samples that **did not have a stated expected drug** contained despropionyl fentanyl (4-ANPP)*
- 17% (1) of samples that **did not have a stated expected drug** contained fentanyl*

***Unexpected noteworthy drug:** “Noteworthy drugs” are drugs that are highly potent, linked to overdose or other adverse effects, or may not be desired by some clients. Noteworthy drugs are called out when they are unexpectedly found in checked samples.

The [Centre on Drug Policy Evaluation](#) is coordinating [Toronto's drug checking service](#). Located within St. Michael's Hospital's MAP Centre for Urban Health Solutions in Toronto, Canada, the Centre on Drug Policy Evaluation strives to improve community health and safety by conducting research and outreach on best practices in drug policy.

(e) drugchecking@cdpe.org | (t) [@drugpolicyctr](https://www.instagram.com/drugpolicyctr) | (f) facebook.com/centreondrugpolicyevaluation

